Literature DB >> 28082339

BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors.

Ja Min Byun1,2,3, Youngil Koh4, Dong-Yeop Shin1, Inho Kim1, Sung-Soo Yoon1, Jeong-Ok Lee2, Soo-Mee Bang2, Ki Hwan Kim3, Sung-Hoon Jung5, Won Sik Lee6, Yong Park7, Jun Ho Jang8, Jae Joon Han9, Ho-Young Yhim10, Dae Sik Kim11, Yoo Jin Lee12, Hyewon Lee13, Yun-Suk Choi14, Seok Lee15.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28082339      PMCID： PMC5477621          DOI： 10.3324/haematol.2016.159988

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Robin Foà; Antonella Vitale; Marco Vignetti; Giovanna Meloni; Anna Guarini; Maria Stefania De Propris; Loredana Elia; Francesca Paoloni; Paola Fazi; Giuseppe Cimino; Francesco Nobile; Felicetto Ferrara; Carlo Castagnola; Simona Sica; Pietro Leoni; Eliana Zuffa; Claudio Fozza; Mario Luppi; Anna Candoni; Ilaria Iacobucci; Simona Soverini; Franco Mandelli; Giovanni Martinelli; Michele Baccarani
Journal:  Blood       Date:  2011-09-19       Impact factor: 22.113

2.  Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.

Authors:  Yves Chalandon; Xavier Thomas; Sandrine Hayette; Jean-Michel Cayuela; Claire Abbal; Françoise Huguet; Emmanuel Raffoux; Thibaut Leguay; Philippe Rousselot; Stéphane Lepretre; Martine Escoffre-Barbe; Sébastien Maury; Céline Berthon; Emmanuelle Tavernier; Jean-François Lambert; Marina Lafage-Pochitaloff; Véronique Lhéritier; Sylvie Chevret; Norbert Ifrah; Hervé Dombret
Journal:  Blood       Date:  2015-04-15       Impact factor: 22.113

3.  Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.

Authors:  Josep-Maria Ribera; Olga García; Albert Oriol; Cristina Gil; Pau Montesinos; Teresa Bernal; José González-Campos; Esperanza Lavilla; Jordi Ribera; Salut Brunet; María-Pilar Martínez; Mar Tormo; Eulàlia Genescà; Pere Barba; Josep Sarrà; María-Carmen Monteserín; Beatriz Soria; Mercedes Colorado; Antònia Cladera; Antoni García-Guiñón; María Calbacho; Alfons Serrano; Xavier Ortín; María Pedreño; Maria-Luz Amigo; Lourdes Escoda; Evarist Feliu
Journal:  Leuk Res       Date:  2015-12-02       Impact factor: 3.156

4.  Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.

Authors:  Marco Vignetti; Paola Fazi; Giuseppe Cimino; Giovanni Martinelli; Francesco Di Raimondo; Felicetto Ferrara; Giovanna Meloni; Achille Ambrosetti; Giovanni Quarta; Livio Pagano; Giovanna Rege-Cambrin; Loredana Elia; Raffaello Bertieri; Luciana Annino; Robin Foà; Michele Baccarani; Franco Mandelli
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

Review 5.  New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia.

Authors:  Elias Jabbour; Susan O'Brien; Marina Konopleva; Hagop Kantarjian
Journal:  Cancer       Date:  2015-04-17       Impact factor: 6.860

6.  BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.

Authors:  Patrizia Comoli; Sabrina Basso; Giovanni Riva; Patrizia Barozzi; Ilaria Guido; Antonella Gurrado; Giuseppe Quartuccio; Laura Rubert; Ivana Lagreca; Daniela Vallerini; Fabio Forghieri; Monica Morselli; Paola Bresciani; Angela Cuoghi; Ambra Paolini; Elisabetta Colaci; Roberto Marasca; Antonio Cuneo; Lorenzo Iughetti; Tommaso Trenti; Franco Narni; Robin Foà; Marco Zecca; Mario Luppi; Leonardo Potenza
Journal:  Blood       Date:  2016-12-07       Impact factor: 22.113

7.  Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Naval Daver; Deborah Thomas; Farhad Ravandi; Jorge Cortes; Rebecca Garris; Elias Jabbour; Guillermo Garcia-Manero; Gautam Borthakur; Tapan Kadia; Michael Rytting; Marina Konopleva; Hagop Kantarjian; Susan O'Brien
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

8.  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.

Authors:  Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Deborah Thomas; Xuelin Huang; Stefan Faderl; Naveen Pemmaraju; Naval Daver; Guillermo Garcia-Manero; Koji Sasaki; Jorge Cortes; Rebecca Garris; C Cameron Yin; Joseph D Khoury; Jeffrey Jorgensen; Zeev Estrov; Zachary Bohannan; Marina Konopleva; Tapan Kadia; Nitin Jain; Courtney DiNardo; William Wierda; Vicky Jeanis; Susan O'Brien
Journal:  Lancet Oncol       Date:  2015-09-30       Impact factor: 41.316

9.  Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

Authors:  Oliver G Ottmann; Barbara Wassmann; Heike Pfeifer; Aristoteles Giagounidis; Matthias Stelljes; Ulrich Dührsen; Marc Schmalzing; Lydia Wunderle; Anja Binckebanck; Dieter Hoelzer
Journal:  Cancer       Date:  2007-05-15       Impact factor: 6.860

10.  Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.

Authors:  D J DeAngelo; K E Stevenson; S E Dahlberg; L B Silverman; S Couban; J G Supko; P C Amrein; K K Ballen; M D Seftel; A R Turner; B Leber; K Howson-Jan; K Kelly; S Cohen; J H Matthews; L Savoie; M Wadleigh; L A Sirulnik; I Galinsky; D S Neuberg; S E Sallan; R M Stone
Journal:  Leukemia       Date:  2014-07-31       Impact factor: 11.528
View more
  4 in total

1.  Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.

Authors:  Nicholas J Short; Keyur P Patel; Maher Albitar; Miguel Franquiz; Rajyalakshmi Luthra; Rashmi Kanagal-Shamanna; Feng Wang; Rita Assi; Guillermo Montalban-Bravo; Jairo Matthews; Wanlong Ma; Sanam Loghavi; Koichi Takahashi; Ghayas C Issa; Steven M Kornblau; Elias Jabbour; Guillermo Garcia-Manero; Hagop M Kantarjian; Zeev Estrov; Farhad Ravandi
Journal:  Blood Adv       Date:  2020-04-28

Review 2.  Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.

Authors:  Nicholas J Short; Hagop Kantarjian; Elias Jabbour; Farhad Ravandi
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

3.  Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia.

Authors:  Daniela V Wenge; Klaus Wethmar; Corinna A Klar; Hedwig Kolve; Tim Sauer; Linus Angenendt; Georg Evers; Simon Call; Andrea Kerkhoff; Cyrus Khandanpour; Torsten Kessler; Rolf Mesters; Christoph Schliemann; Jan-Henrik Mikesch; Christian Reicherts; Monika Brüggemann; Wolfgang E Berdel; Georg Lenz; Matthias Stelljes
Journal:  Cancers (Basel)       Date:  2022-01-23       Impact factor: 6.639

Review 4.  Management of older adults with acute lymphoblastic leukemia: challenges & current approaches.

Authors:  Yazeed Sawalha; Anjali S Advani
Journal:  Int J Hematol Oncol       Date:  2018-04-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.